Effect of maternal SSRI/SNRI treatment in pregnancy on postanatal adaptation of a term newborn

Česká verzia

Authors: H. Tobrmanová
Authors place of work: Mulačova nemocnice, s. r. o., Plzeň
Published in the journal: Čes-slov Neonat 2022; 28 (2): 96-99.
Category: Reviews

Summary

The increasing prevalence of depression and anxiety disorders in the population is reflected in the increased number of pregnant and breastfeeding women being treated with antidepressants/anxiolytics from the selective serotonin reuptake inhibitor (SSRI) and serotonin norepinephrine reuptake inhibitor (SNRI) groups. These drugs pass through the placenta and are excreted into breast milk, which is why attention must be paid to the potential risks to the fetus and newborn. Both these medications and untreated psychiatric disorder can negatively affect fetal development and postanatal adaptation of the newborn [1].

Keywords:

SSRI – depression – withdrawal syndrome – neonate

Zdroje

1. Šebela A, Hanka J, Goetz M, Mohr P. Psychofarmaka během těhotenství: mírní, nebo zvyšují riziko pro plod? Část první: antidepresiva, antipsychotika. Pediatrie pro praxi 2017; 18(5): 282−286.

2. Mocková A, Nováková V, Lucková Z, Dort J. Deprese a antidepresivní terapie matek z pohledu neonatologa. Pediatrie pro praxi 2012; 13(3): 188−192.

3. Kašpárek T. SSRI v graviditě a laktaci. Psychiatrie pro praxi 2013; 14(1): 37.

4. Forsberg L, Navér L, Gustafsson L, Wide K. Neonatal adaptation in infants prenataly exposed to antidepressants – clinical monitoring using neonatal abstinence score. PLoS 2014; 9(11): e111327. Dostupné na: https://doi.org/10.1371/journal. pone.0111327

5. Shea A, Oberlander T, Rurak D. Fetal serotonin reuptake inhibitor antidepressant exposure: maternal and fetal factors. Psychiatry 2012; 57(9): 523−5295.

6. Barclay L, Vega Ch. Prenatal exposure to SSRIs linked to low birth weight, respiratory distress. Archives of General Psychiatry 2006; 63: 898−906.

7. Kautzky A, Slamanig R, Unger A, Höflich A. Neonatal outcome and adaptation after in utero exposure to antidepressants: a systematic review and meta-analysis. Acta Psychiatrica Scandinavica 2022; 145: 6−28.

8. Horáčková H, Karhoda R, Červený L, Váchalová V, Ebner R, Abad C, Staud F. Effect of selected antidepressants on placental homeostasis od serotonin: maternal and fetal Perspectives. Pharmaceutics 2021; 13: 1306. https//doi.org/10.3390/pharmaceutics13081306

9. Wang J, Cosci F. Maternal withdrawal syndrome following late in utero exposure to selective serotonin reuptake inhibitors: a systematic review and meta-analysis of observational studies. Psychoterapapy and Psychosomatics 2021; 90(5): 299−307.

10. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptakce inhibitors in term infants. Archive of Pediatrics and Adolescent Medicine 2006; 160: 173−176.

11. Uguz F. A new safety scoring system for the use of psychotropic drugs during lactation. American Journal of Therapeutics 2021; 28(1): 118−126.

12. Wiggs KK, Sujan AC, Rickert ME, Quinn PD, Larsson H, Lichtebstein P, D´Onofrio B, Oberg AS. Maternal serotonergic antidepressant use in pregnancy and risk of seizures in children. Neurology 2022; 98: 2329−2233.